A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid

Leukemia Research

Volumn 33, Issue 6, 2009, Pages 779-787

  Ryningen, Anita ^a,b   Stapnes, Camilla ^a,b   Lassalle, Philippe ^c   Corbascio, Matthias ^b   Gjertsen, Bjørn Tore ^a,b   Bruserud, Øystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Acute myelogenous leukemia; All trans retinoic acid; Theophylline; Therapy; Valproic acid

Indexed keywords

ANGIOPOIETIN 2; CELL MARKER; CYTOKINE; HYDROXYUREA; MERCAPTOPURINE; PROTEIN ENDOCAN; RETINOIC ACID; THEOPHYLLINE; THO DUR; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LIVER TOXICITY; MALE; METABOLIC DISORDER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETICULOCYTE COUNT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; BLOOD CELL COUNT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOGLYCANS; RISK FACTORS; SURVIVAL ANALYSIS; THEOPHYLLINE; TRETINOIN; VALPROIC ACID;

EID: 63349103376     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.10.005     Document Type: Article

References (23)

1. Smith M., Barnett M., Bassan R., Gatta G., Tondini C., and Kern W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 50 (2004) 197-222
2. Bruserud O., Stapnes C., Ersvaer E., Ryningen A., and Gjertsen B.T. Histone deacetylase inhibitors in cancer treatment: a review of clinical toxicity and immunosuppresion, effects on normal hematopoiesis and modulation of gene expression in cancer cells. Curr Pharmaceut Biotechnol 8 (2007) 388-400
3. Kuendgen A., Strupp C., Aivado M., Bernhardt A., Hildebrandt B., Haas R., et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104 (2004) 1266-1269
4. Pilatrino C., Cilloni D., Messa E., Morotti A., Giugliano E., Pautasso M., et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 104 (2005) 101-109
5. Bug G., Ritter M., Wassmann B., Schoch C., Heinzel T., Schwarz K., et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104 (2005) 2717-2725
6. Raffoux E., Chaibi P., Dombret H., and Degos L. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 90 (2005) 986-988
7. Ryningen A., Ersvaer E., Oyan A.M., Kalland K.H., Vintermyr O.K., Gjertsen B.T., et al. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. Leuk Res 30 (2006) 1531-1540
8. Ryningen A., Stapnes C., and Bruserud O. Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting. Leuk Res 31 (2007) 1303-1313
9. Bruserud O., Ryningen A., Olsnes A.M., Stordrange L., Oyan A.M., Kalland K.H., et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 92 (2007) 332-341
10. Bruserud O., Ryningen A., Wergeland L., Glenjen N.I., and Gjertsen B.T. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 89 (2004) 391-402
11. Bechard D., Meignin V., Scherpereel A., Oudin S., Kervoaze G., Bertheau P., et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 37 (2000) 417-425
12. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al., Revised recommendations of the International Working Group for Diagnosis. Standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21 (2003) 4642-4649
13. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108 (2006) 419-425
14. Stapnes C., Ryningen A., Hatfield K., Oyan A.M., Eide G.E., Corbascio M., et al. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. Int J Oncol 31 (2007) 1529-1538
15. Grigoriu B.D., Depontieu F., Scherpereel A., Gourcerol D., Devos P., Ouatas T., et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 12 (2006) 4575-4582
16. Kuendgen A., Schmid M., Schlenk R., Knipp S., Hildebrandt B., Steidl C., et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106 (2006) 112-119
17. Visani G., Malagola M., Piccaluga P.P., and Isidori A. Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy?. Leuk Lymphoma 45 (2004) 1531-1538
18. De Felice L., Tatarelli C., Mascolo M.G., Gregorj C., Agostini F., Fiorini R., et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res 65 (2005) 1505-1513
19. Hellebrekers D.M., Castermans K., Vire E., Dings R.P., Hoebers N.T., Mayo K.H., et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 66 (2006) 10770-10777
20. Axel D.I., Frigge A., Dittmann J., Runge H., Spyridopoulos I., Riessen R., et al. All-trans retinoic acid regulates proliferation, migration, differentiation, and extracellular matrix turnover of human arterial smooth muscle cells. Cardiovasc Res 49 (2001) 851-862
21. Marchetti M., Vignoli A., Bani M.R., Balducci D., Barbui T., and Falanga A. All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties. Haematologica 88 (2003) 895-905
22. Ryningen A., Stapnes C., Paulsen K., Lassalle P., Gjertsen B.T., and Bruserud O. In vivo biological effects of ATRA in the treatment of AML. Exp. Opin. Investig. Drugs 17 11 (2008) 1623-1633
23. Schliemann C., Bieker R., Thoennissen N., Gerss J., Liersch R., Kessler T., et al. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 21 (2007) 1901-1906